
INBX
Healthcare · Biotechnology · $1.23B market cap
$83.30-4.45 (-5.1%)Nov 13, 4:21 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +1.4% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 13, 2026 | After the close | -2.35 | -2.46 | -4.7% |
| Aug 13, 2026 | After the close | -2.50 | -2.34 | +6.4% |
| May 14, 2026 | After the close | -1.20 | -2.15 | -79.2% |
| Mar 23, 2026 | Time not confirmed | -1.63 | -2.11 | -29.4% |
| Nov 14, 2025 | Before the open | -1.72 | -2.28 | -32.6% |
| Aug 13, 2025 | After the close | -2.60 | -1.85 | +28.8% |
| May 14, 2025 | After the close | -3.12 | -2.80 | +10.3% |
| Mar 17, 2025 | Time not confirmed | -1.44 | -3.09 | -114.6% |
| Nov 14, 2024 | After the close | -3.70 | -2.84 | +23.2% |
| Aug 13, 2024 | Time not confirmed | -1.52 | 125.48 | +8355.3% |
| May 29, 2024 | Time not confirmed | -1.04 | -1.44 | -38.5% |
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic…